Literature DB >> 23434730

A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).

V Sardnal, A Rouquette, S Kaltenbach, C Bally, V Chesnais, C Leschi, L Ades, V Santini, S Park, A Toma, P Fenaux, F Dreyfus, M Fontenay, O Kosmider.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23434730     DOI： 10.1038/leu.2013.59

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

Review 1.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

2.  Cereblon expression is a prognostic marker in newly diagnosed POEMS syndrome treated with lenalidomide plus dexamethasone.

Authors:  Qian-Qian Cai; Xue-Min Gao; Jing Le; Hao Zhao; Hao Cai; Xin-Xin Cao; Jian Li
Journal:  Ann Hematol       Date:  2021-04-10       Impact factor: 3.673

3.  Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Authors:  A Toma; O Kosmider; S Chevret; J Delaunay; A Stamatoullas; C Rose; O Beyne-Rauzy; A Banos; A Guerci-Bresler; S Wickenhauser; D Caillot; K Laribi; B De Renzis; D Bordessoule; C Gardin; B Slama; L Sanhes; B Gruson; P Cony-Makhoul; B Chouffi; C Salanoubat; R Benramdane; L Legros; E Wattel; G Tertian; K Bouabdallah; F Guilhot; A L Taksin; S Cheze; K Maloum; S Nimuboma; C Soussain; F Isnard; E Gyan; R Petit; J Lejeune; V Sardnal; A Renneville; C Preudhomme; M Fontenay; P Fenaux; F Dreyfus
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

Review 4.  There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.

Authors:  Amer M Zeidan; Rami S Komrokji
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 5.  Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.

Authors:  Abdallah Abou Zahr; Ehab Saad Aldin; Rami S Komrokji; Amer M Zeidan
Journal:  J Blood Med       Date:  2014-12-22

6.  Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.

Authors:  Aude Le Roy; Thomas Prébet; Rémy Castellano; Armelle Goubard; Florence Riccardi; Cyril Fauriat; Samuel Granjeaud; Audrey Benyamine; Céline Castanier; Florence Orlanducci; Amira Ben Amara; Frédéric Pont; Jean-Jacques Fournié; Yves Collette; Jean-Louis Mege; Norbert Vey; Daniel Olive
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

7.  Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Authors:  Phoebe A Huang; Shaunna L Beedie; Cindy H Chau; David J Venzon; Sheryl Gere; Dickran Kazandjian; Neha Korde; Sham Mailankody; Ola Landgren; William D Figg
Journal:  Sci Rep       Date:  2019-10-16       Impact factor: 4.379

8.  Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.

Authors:  A Thakurta; A K Gandhi; M F Waldman; C Bjorklund; Y Ning; D Mendy; P Schafer; A Lopez-Girona; S Lentzsch; S A Schey; Y Calle; R Chelliah; R Z Orlowski; A Madan; H Avet-Loiseau; R Chopra
Journal:  Leukemia       Date:  2013-10-29       Impact factor: 11.528

9.  Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.

Authors:  E Negoro; T Radivoyevitch; C Polprasert; V Adema; N Hosono; H Makishima; B Przychodzen; C Hirsch; M J Clemente; A Nazha; V Santini; K L McGraw; A F List; F Sole; M A Sekeres; J P Maciejewski
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528

10.  Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.

Authors:  Leylah M Drusbosky; Christopher R Cogle
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.